{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/prescribing-information/ssris/","result":{"pageContext":{"chapter":{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs","depth":2,"htmlHeader":"<!-- begin field b7956a5a-5fdd-47bf-80bf-ab1a00fb234a --><h2>Selective serotonin reuptake inhibitors (SSRIs)</h2><!-- end field b7956a5a-5fdd-47bf-80bf-ab1a00fb234a -->","summary":"","htmlStringContent":"<!-- begin item c8737299-05f0-449e-b788-ab1a00fb22a7 --><!-- end item c8737299-05f0-449e-b788-ab1a00fb22a7 -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"970c4720-0ae8-5f93-9e2c-1ffdddaa79c4","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1ec87761-4d93-49e3-ad6d-ab1a00fbc925 --><h3>Contraindications and cautions</h3><!-- end field 1ec87761-4d93-49e3-ad6d-ab1a00fbc925 -->","summary":"","htmlStringContent":"<!-- begin item f664540a-bf76-4465-8080-ab1a00fbc8ca --><!-- begin field 5b0b8bdc-81b7-4d74-9323-ab1a00fbc925 --><ul><li><strong>Do not prescribe selective serotonin reuptake inhibitors (SSRIs) to people:</strong><ul><li>In a manic phase of bipolar disorder.</li><li>With poorly controlled epilepsy.</li><li>With known QT interval prolongation, or congenital long QT syndrome (citalopram and escitalopram).</li><li>Taking other medicines that are known to prolong the QT interval (citalopram and escitalopram).</li><li>With severe hepatic impairment (sertraline). </li></ul></li><li><strong>Prescribe SSRIs with caution</strong> <strong>to people with:</strong><ul><li>A history of bleeding disorders (especially gastrointestinal bleeding).</li><li>A history of mania.</li><li>Cardiac disease.</li><li>Diabetes mellitus.</li><li>Epilepsy (discontinue if convulsions develop).</li><li>Hepatic impairment.</li><li>Risk factors for QT-interval prolongation (citalopram and escitalopram).</li><li>Renal impairment (sertraline). </li><li>Significant bradycardia (citalopram and escitalopram).</li></ul></li><li><strong>Also prescribe SSRIs with caution to people:</strong><ul><li>Susceptible to angle-closure glaucoma.</li><li>Undergoing concurrent electroconvulsive therapy.</li><li>Who have had a recent myocardial infarction (citalopram and escitalopram).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 5b0b8bdc-81b7-4d74-9323-ab1a00fbc925 --><!-- end item f664540a-bf76-4465-8080-ab1a00fbc8ca -->","subChapters":[]},{"id":"20cab5d8-335d-525c-9ee9-105beac6ce1f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 09ca7959-7891-4c2d-b0a0-ab1a00fbdeff --><h3>Adverse effects</h3><!-- end field 09ca7959-7891-4c2d-b0a0-ab1a00fbdeff -->","summary":"","htmlStringContent":"<!-- begin item cac426d2-0480-4ed9-9f5d-ab1a00fbded9 --><!-- begin field 5d49f4d8-6524-4dac-b775-ab1a00fbdeff --><ul><li><strong>Cardiac </strong>— palpitations (common); tachycardia (uncommon); QT interval prolongation, torsade de pointes (frequency unknown).<ul><li><strong>Rarely:</strong> myocardial infarction, bradycardia.</li></ul></li><li><strong>Gastrointestinal </strong>— diarrhoea, nausea, dry mouth (very common); abdominal pain, constipation, vomiting, dyspepsia (common); microscopic colitis, pancreatitis (frequency unknown).<ul><li><strong>Rarely:</strong> melaena, stomatitis, tongue/mouth ulceration, glossitis.</li></ul></li><li><strong>Nervous system </strong>— headache, dizziness, somnolence (very common); paraesthesia, tremor, hypertonia, dysgeusia (common); convulsions, hypokinesia, speech disorder (uncommon).<ul><li><strong>Rarely</strong>: coma, dyskinesia, sensory disturbance.</li><li><strong>Frequency unknown</strong>: movement disorders, serotonin syndrome, neuroleptic malignant syndrome.</li></ul></li><li><strong>Psychiatric </strong>—insomnia (very common); depression, nightmares, agitation, anxiety (common).<ul><li><strong>Rarely: </strong>psychotic disorder, paranoia, suicidal thoughts and behaviour.</li></ul></li><li><strong>Skin and subcutaneous tissue</strong> — rash, hyperhidrosis (common); oedema, purpura, alopecia, pruritus, urticaria (uncommon).<ul><li><strong>Rarely:</strong> dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis.</li></ul></li><li><strong>Bone fractures</strong> — epidemiological data show that SSRIs are associated with an increased risk of fractures. However, the mechanism leading to this increased risk is unclear.</li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Appetite and weight changes.</li><li>Arthralgia, myalgia.</li><li>Blurred vision, mydriasis.</li><li>Hepatitis, jaundice.</li><li>Gastrointestinal, or gynaecological haemorrhage.</li><li>Hyponatraemia, syndrome of inappropriate anti-diuretic hormone secretion (SIADH).</li><li>Increased cholesterol levels.</li><li>Pharyngitis.</li><li>Sexual dysfunction (which may persist following discontinuation).</li><li>Tinnitus.</li><li>Thrombocytopenia.</li><li>Urinary problems.</li><li>Yawning, interstitial lung disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2020a</a>]</p><!-- end field 5d49f4d8-6524-4dac-b775-ab1a00fbdeff --><!-- end item cac426d2-0480-4ed9-9f5d-ab1a00fbded9 -->","subChapters":[]},{"id":"56dc625b-729e-5134-bc9b-c56cb3c2e47a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field de42d942-881c-4fcd-b841-ab1a00fbea09 --><h3>Drug interactions</h3><!-- end field de42d942-881c-4fcd-b841-ab1a00fbea09 -->","summary":"","htmlStringContent":"<!-- begin item 30a6f33f-8eb4-46b9-bbd6-ab1a00fbe9e6 --><!-- begin field c6b01ad4-a5ca-421a-bf9f-ab1a00fbea09 --><ul><li><strong>Antiepileptics</strong> — SSRIs can reduce the seizure threshold.</li><li><strong>Antidiabetics</strong> — SSRIs can affect diabetic control. Monitor blood glucose when starting or stopping an SSRI.</li><li><strong>Aspirin, NSAIDs, anticoagulants and antiplatelets </strong>— increased risk of bleeding if taken concomitantly with SSRIs.</li><li><strong>Carbamazepine</strong> — levels of sertraline may be reduced.</li><li><strong>Cocaine</strong> — possibly an increased risk of bleeding with citalopram. Prescribers should enquire about illicit drug use before prescribing SSRIs. </li><li><strong>Coumarins</strong> (for example warfarin) — SSRIs possibly enhance anticoagulant effect of coumarins.<ul><li>Consider frequent monitoring of the INR.</li></ul></li><li><strong>Cyproheptadine</strong> — antidepressant effect of SSRIs possibly antagonised by cyproheptadine.</li><li><strong>Grapefruit juice</strong> — levels of sertraline may be modestly increased.</li><li><strong>HIV protease inhibitors</strong> (for example, lopinavir, atazanavir) — efficacy of SSRIs may be reduced. Monitor and adjust dose of SSRI if required.</li><li><strong>Lithium</strong> — concurrent us with SSRI may cause serotonin syndrome or neuroleptic malignant syndrome. In addition, lithium has been associated with QT prolongation and concomitant use may increase this risk. Monitor for adverse effects.</li><li><strong>Monoamine oxidase inhibitors</strong> (MAOIs) — concurrent use is contraindicated. Fatal reactions may occur (serotonin syndrome or neuroleptic malignant syndrome).</li><li><strong>SNRIs </strong>(venlafaxine, duloxetine) — increased risk of serotonin syndrome or neuroleptic malignant syndrome when given concomitantly with an SSRI. Monitor for symptoms of serotonin syndrome or neuroleptic malignant syndrome (such as fever, tremors, diarrhoea, agitation).<ul><li>Venlafaxine may also increase risk of QT interval prolongation if taken concomitantly with an SSRI. Consider ECG monitoring.</li></ul></li><li><strong>Tamoxifen</strong> — avoid concurrent use with fluoxetine or paroxetine. Fluoxetine and paroxetine are potent inhibitors of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy.</li><li><strong>Other sedative drugs (alcohol, barbiturates, benzodiazepines)</strong> — SSRIs are sedating and co-administration with other sedating drugs may have a synergistic effect.</li><li><strong>Other drugs, which if taken with SSRIs may increase the risk of serotonin syndrome or neuroleptic malignant syndrome, include:</strong><ul><li>Opioids — fentanyl, tramadol.</li><li>St John’s wort — avoid concurrent use.</li><li>Triptans — sumatriptan, naratriptan.</li><li>Vortioxetine.</li></ul></li><li><strong>QT interval prolongation </strong>— some SSRIs are associated with QT interval prolongation and torsade de pointes. Concurrent use with other drugs that prolong the QT interval drugs may increase the risk. These include:<ul><li>Antiarrhythmics — amiodarone, dronedarone, quinidine.<ul><li>Dronedarone may also increase sertraline levels.</li></ul></li><li>Antipsychotics — phenothiazine derivatives, pimozide, haloperidol.<ul><li>Sertraline may also increase pimozide levels.</li></ul></li><li>Tricyclic antidepressants (TCA) — clomipramine, imipramine.<ul><li>SSRIs may also increase levels of TCAs.</li></ul></li><li>Antibiotics — sparfloxacin, moxifloxacin.</li><li>Halofantrine, saquinavir, sildenafil, methadone.</li></ul></li><li><strong>Paroxetine may increase plasma concentrations of some drugs, including:</strong><ul><li>Aripiprazole, clozapine, risperidone.</li><li>Atomoxetine.</li><li>Darifenacin.</li><li>Galantamine. </li><li>Metoprolol.</li><li>Perphenazine.</li><li>Procyclidine.</li><li>Propafenone.</li><li>Ranolazine</li><li>Tricyclic antidepressants.</li><li>Vortioxetine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">MHRA, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2021</a>]</p><!-- end field c6b01ad4-a5ca-421a-bf9f-ab1a00fbea09 --><!-- end item 30a6f33f-8eb4-46b9-bbd6-ab1a00fbe9e6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}